000			01901nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aTherapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
546			_aEnglish[eng]
650			_amonoclonal antibody||NSCLC||immunotherapy||ELISA||pharmacokinetics||pharmacogenetics||anti-PD-1 monoclonal antibodies||anti-acetylcholine receptor (AChR) antibody||B cell||immune checkpoint blockade||immune-related adverse events (irAEs)||myasthenia gravis (MG)||non-small-cell lung cancer (NSCLC)||nivolumab||programmed cell death ligand 1 (PD-L1)||T cell||tetraspanins||cancer||Tspan8||radioimmunotherapy||immune-checkpoint inhibitors||LDH||biomarkers||Ang-2||antiangiogenic therapy||in vivo imaging||radio- and chemotherapy||VEGF-A||cancer therapy||neovascularization||angiogenesis||tumor microenvironment||colorectal cancer||antibody||NK cells||ADCC||CD133||prominin-1||gold nanoparticles||antibody-drug conjugates||cell penetrating peptide||HIV-1 TAT||active-targeting||targeted delivery||trastuzumab||MMAE||valine-citrulline||affibody||drug conjugates||hepatic uptake||DM1||dermatooncology||immune checkpoints||monoclonal antibodies||passive immunotherapy||canine B-cell lymphoma||DLA-DR||HLA-DR||antibody-drug conjugate||ADC||methotrexate||tumor immunity||combination therapy||multiple myeloma (MM)||monoclonal antibodies (mAbs)||antibody products||B cell maturation antigens (BCMAs)||bispecific T cell engagers (BiTEs®)||checkpoint inhibitors 1||protein structure 2||pharmacokinetics 3||drug optimization 4||HER2-positive breast cancer||metastatic disease||neoadjuvant and adjuvant therapy||targeted therapy||acute myeloid leukemia||CD123||IL3RA||kinesin spindle protein inhibitor
700			_aKayser, Veysel
856			_uhttps://mdpi.com/books/pdfview/book/4898
942			_cEB
999			_c29818 _d29818